Resideo Announces First Quarter 2025 Financial Results; Reaffirms 2025 Outlook
Net revenue was $1.77 billion, up 19% year-over-year, at the high-end of outlook range; reflects mid-single-digit organic revenue(1) growth at both ADI and Products... Read more.
GRAND CANYON EDUCATION, INC. REPORTS FIRST QUARTER 2025 RESULTS
PHOENIX, May 6, 2025 /PRNewswire/ — Grand Canyon Education, Inc. (NASDAQ: LOPE), (“GCE” or the “Company”), is a publicly traded education... Read more.
Flotek Provides Strong 2025 Outlook in Connection with Announcing Robust First Quarter 2025 Revenue and Profit Growth
HOUSTON, May 6, 2025 /PRNewswire/ — Flotek Industries, Inc. (“Flotek” or the “Company”) (NYSE: FTK) today announced operational and... Read more.
Fathom Holdings Sets First Quarter 2024 Conference Call for Tuesday, May 13, 2025, at 5:00 p.m. ET
CARY, N.C., May 6, 2025 /PRNewswire/ — Fathom Holdings Inc. (Nasdaq: FTHM) (“Fathom” or the “Company”), a national, technology-driven,... Read more.
Revolve Group Announces First Quarter 2025 Financial Results
LOS ANGELES, May 6, 2025 /PRNewswire/ — Revolve Group, Inc. (NYSE: RVLV), the next-generation fashion retailer for Millennial and Generation Z consumers,... Read more.
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 6, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in May. Chief Executive... Read more.
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8... Read more.
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine... Read more.
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased... Read more.
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
– Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track... Read more.